Asset Details
Do you wish to reserve the book?
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
Do you wish to request the book?
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
High GPR56 surface expression correlates with a leukemic stem cell gene signature in CD34‐positive AML
2019
Overview
Acute myeloid leukemia (AML) is driven by a minor fraction of leukemic stem cells (LSCs) whose persistence is considered being the primary cause of disease relapse. A detailed characterization of the surface immunophenotype of LSCs to discriminate them from bulk leukemic blasts may enable successful targeting of this population thereby improving patient outcomes in AML. To identify surface markers, which may reflect LSC activity at diagnosis, we performed a detailed analysis of 16 putative LSC markers in CD34/38 leukemic subcompartments of 150 diagnostic AML samples using multicolor flow cytometry. The most promising markers were then selected to determine a possible correlation of their expression with a recently published LSC gene signature. We found GPR56 and CLL‐1 to be the most prominently differently expressed surface markers in AML subcompartments. While GPR56 was highest expressed within the LSC‐enriched CD34+38− subcompartment as compared to CD34+38+ and CD34− leukemic bulk cells, CLL‐1 expression was lowest in CD34+38− leukemic cells and increased in CD34+38+ and CD34− blasts. Furthermore, high GPR56 surface expression in CD34+38− leukemic cells correlated with a recently published LSC gene expression signature and was associated with decreased overall survival in patients receiving intensive chemotherapy. In contrast, CLL‐1 expression correlated inversely with the LSC gene signature and was not informative on outcome. Our data strongly support GPR56 as a promising clinically relevant marker for identifying leukemic cells with LSC activity at diagnosis in CD34‐positive AML. In a comprehensive analysis of 16 putative leukemic stem cell (LSC) markers, we identified high GPR56 surface expression in LSC‐enriched CD34+38‐ leukemic cells and its correlation with a LSC gene signature in CD34‐positive AML. Since GPR56 expression also correlated with adverse outcome, GPR56 expression may serve as a clinically relevant marker for LSC activity and outcome in AML. In contrast, CLL‐1 expression correlated inversely with an LSC gene signature and may therefore have limited potential for identification of LSC among AML cells.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Adult
/ Aged
/ Antigens
/ Antineoplastic Agents - therapeutic use
/ Biomarkers, Tumor - metabolism
/ Chronic lymphocytic leukemia
/ CLL‐1
/ Female
/ Gene Expression Profiling - methods
/ GPR56
/ Humans
/ Lectins, C-Type - metabolism
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - genetics
/ Leukemia, Myeloid, Acute - metabolism
/ Leukemia, Myeloid, Acute - pathology
/ Male
/ Neoplasm Proteins - metabolism
/ Neoplastic Stem Cells - immunology
/ Neoplastic Stem Cells - metabolism
/ Patients
/ Receptors, G-Protein-Coupled - metabolism
/ Receptors, Mitogen - metabolism
/ Software
